Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7390720 | Value in Health Regional Issues | 2014 | 10 Pages |
Abstract
There is a lack of successful therapies for patients with HCV who have previously failed to achieve sustained virological response or are ineligible for interferon-alfa-based therapies. Results demonstrate that the provision of an alternative, interferon-alfa-free regimen, such as DCV + ASV, offers significant value in terms of avoiding life-threatening liver complications and increasing patients' quality of life.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Phil PhD, Thomas MSc, Samantha BSc, Yong PhD, Anupama MS, Kristine MS, Isao PhD, Melanie PhD, Scott M. PhD, Masahiro MD, Sachie PhD, Ann PhD, Hiromitsu MD,